SMMNY - Stereotaxis: Driving Robotic Revolution In Endovascular Surgery; Acquisition Potential Rising
- "Stereotaxis reminds me in many ways of Intuitive Surgical in our early years." - Executive VP & CMO of Intuitive Surgical and new Stereotaxis board member.
- Innovation Day showcased significant catalysts ahead including multiple regulatory milestones & commercial product launches; company well positioned to become the Intuitive Surgical of endovascular surgery.
- Acquisition potential rising with expansion of clinical indications & TAM now exceeding $30 Billion; believe Philips, Intuitive Surgical, or Johnson & Johnson at top of list of possible acquirors.
- Upcoming launches of in-house catheters/guidewires & mobile RMN robot game-changers that transform lengthy fixed-install sales cycle to much shorter sales cycle with lease & usage-based models.
- Fundamental growth story firmly underway with sell-side consensus estimates showing revenue growth of 30% in FY21 to $35MM, 27% in FY22 to $44MM, and 41% to $62MM in FY23.
For further details see:
Stereotaxis: Driving Robotic Revolution In Endovascular Surgery; Acquisition Potential Rising